Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
16 04 2019
Historique:
pubmed: 9 4 2019
medline: 22 1 2020
entrez: 9 4 2019
Statut: ppublish

Résumé

The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include. This guidance statement is derived from an appraisal of selected guidelines from around the world that address breast cancer screening, as well as their included evidence. All national guidelines published in English between 1 January 2013 and 15 November 2017 in the National Guideline Clearinghouse or Guidelines International Network library were included. In addition, the authors selected other guidelines commonly used in clinical practice. Web sites associated with all selected guidelines were checked for updates on 10 December 2018. The AGREE II (Appraisal of Guidelines for Research and Evaluation II) instrument was used to evaluate the quality of guidelines. The target audience is all clinicians, and the target patient population is all asymptomatic women with average risk for breast cancer. In average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breast cancer with mammography before age 50 years. Discussion should include the potential benefits and harms and a woman's preferences. The potential harms outweigh the benefits in most women aged 40 to 49 years. In average-risk women aged 50 to 74 years, clinicians should offer screening for breast cancer with biennial mammography. In average-risk women aged 75 years or older or in women with a life expectancy of 10 years or less, clinicians should discontinue screening for breast cancer. In average-risk women of all ages, clinicians should not use clinical breast examination to screen for breast cancer.

Identifiants

pubmed: 30959525
pii: 2730520
doi: 10.7326/M18-2147
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

547-560

Investigateurs

Mary Ann Forciena (MA)
Nick Fitterman (N)
Carrie A Horwitch (CA)
Linda L Humphrey (LL)
Alfonso Iorio (A)
Devan Kansagara (D)
Jennifer S Lin (JS)
Scott Manaker (S)
Michael Maroto (M)
Robert M McLean (RM)
Reem A Mustafa (RA)
Janice E Tufte (JE)
Sandeep Vijan (S)
Timothy J Wilt (TJ)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn

Auteurs

Amir Qaseem (A)

American College of Physicians, Philadelphia, Pennsylvania (A.Q.).

Jennifer S Lin (JS)

Kaiser Permanente Northwest, Portland, Oregon (J.S.L.).

Reem A Mustafa (RA)

University of Kansas Medical Center, Kansas City, Kansas (R.A.M.).

Carrie A Horwitch (CA)

Virginia Mason Medical Center, Seattle, Washington (C.A.H.).

Timothy J Wilt (TJ)

Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota (T.J.W.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH